Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-HIV Agents | 164 | 2023 | 664 | 27.320 |
Why?
|
Pre-Exposure Prophylaxis | 107 | 2023 | 174 | 20.330 |
Why?
|
HIV Infections | 190 | 2023 | 2459 | 16.730 |
Why?
|
Tenofovir | 97 | 2023 | 200 | 13.200 |
Why?
|
Emtricitabine | 71 | 2023 | 146 | 11.430 |
Why?
|
Adenine | 54 | 2023 | 223 | 9.160 |
Why?
|
Medication Adherence | 84 | 2023 | 556 | 7.590 |
Why?
|
Organophosphates | 37 | 2023 | 90 | 6.560 |
Why?
|
Transgender Persons | 33 | 2023 | 135 | 3.790 |
Why?
|
Homosexuality, Male | 39 | 2022 | 166 | 3.460 |
Why?
|
Dried Blood Spot Testing | 24 | 2023 | 68 | 3.440 |
Why?
|
Organophosphonates | 14 | 2015 | 94 | 2.970 |
Why?
|
Zidovudine | 14 | 2012 | 77 | 2.790 |
Why?
|
Lamivudine | 12 | 2023 | 59 | 2.710 |
Why?
|
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 10 | 2020 | 14 | 2.680 |
Why?
|
Tandem Mass Spectrometry | 22 | 2023 | 421 | 2.640 |
Why?
|
Sexual and Gender Minorities | 16 | 2022 | 137 | 2.560 |
Why?
|
Leukocytes, Mononuclear | 22 | 2023 | 509 | 2.510 |
Why?
|
HIV-1 | 23 | 2023 | 776 | 2.390 |
Why?
|
Deoxycytidine | 8 | 2015 | 136 | 2.330 |
Why?
|
Disease Transmission, Infectious | 10 | 2018 | 56 | 2.280 |
Why?
|
Alcoholic Beverages | 3 | 2022 | 17 | 2.230 |
Why?
|
Chromatography, Liquid | 18 | 2023 | 355 | 2.090 |
Why?
|
HIV Protease Inhibitors | 13 | 2016 | 64 | 2.030 |
Why?
|
Oligopeptides | 10 | 2015 | 252 | 2.020 |
Why?
|
Antiviral Agents | 13 | 2019 | 654 | 1.910 |
Why?
|
Humans | 269 | 2023 | 118972 | 1.850 |
Why?
|
Anti-Retroviral Agents | 14 | 2023 | 208 | 1.830 |
Why?
|
Adult | 136 | 2023 | 31512 | 1.820 |
Why?
|
Deoxyadenine Nucleotides | 3 | 2016 | 13 | 1.750 |
Why?
|
Deoxycytosine Nucleotides | 3 | 2016 | 11 | 1.750 |
Why?
|
Female | 170 | 2023 | 61564 | 1.750 |
Why?
|
Male | 166 | 2023 | 57801 | 1.730 |
Why?
|
Thymine Nucleotides | 6 | 2016 | 15 | 1.710 |
Why?
|
Young Adult | 75 | 2023 | 10793 | 1.620 |
Why?
|
Pyridines | 7 | 2013 | 440 | 1.600 |
Why?
|
Atazanavir Sulfate | 9 | 2016 | 41 | 1.600 |
Why?
|
Hair | 9 | 2020 | 68 | 1.570 |
Why?
|
Blood Chemical Analysis | 11 | 2019 | 95 | 1.460 |
Why?
|
HIV Seropositivity | 9 | 2023 | 111 | 1.390 |
Why?
|
Prospective Studies | 45 | 2023 | 6471 | 1.380 |
Why?
|
Reverse Transcriptase Inhibitors | 15 | 2023 | 81 | 1.330 |
Why?
|
Cytidine Triphosphate | 6 | 2023 | 15 | 1.280 |
Why?
|
Alcohol Drinking | 7 | 2023 | 652 | 1.230 |
Why?
|
Cytochrome P-450 CYP3A | 5 | 2012 | 60 | 1.220 |
Why?
|
Middle Aged | 76 | 2021 | 27617 | 1.200 |
Why?
|
Polyphosphates | 6 | 2022 | 32 | 1.160 |
Why?
|
Primary Health Care | 6 | 2021 | 1560 | 1.130 |
Why?
|
Micrognathism | 2 | 2016 | 10 | 1.120 |
Why?
|
Osteogenesis, Distraction | 2 | 2016 | 11 | 1.120 |
Why?
|
Chemoprevention | 7 | 2018 | 89 | 1.110 |
Why?
|
Adolescent | 74 | 2023 | 18480 | 1.090 |
Why?
|
Alcoholism | 5 | 2018 | 717 | 0.990 |
Why?
|
HIV | 12 | 2023 | 210 | 0.980 |
Why?
|
Drug Monitoring | 5 | 2022 | 187 | 0.950 |
Why?
|
Viral Load | 14 | 2023 | 419 | 0.950 |
Why?
|
Phosphorous Acids | 2 | 2019 | 12 | 0.880 |
Why?
|
Pharmacogenetics | 3 | 2016 | 151 | 0.870 |
Why?
|
Dideoxynucleotides | 7 | 2023 | 14 | 0.850 |
Why?
|
Directly Observed Therapy | 3 | 2022 | 14 | 0.840 |
Why?
|
Ethanol | 4 | 2023 | 575 | 0.830 |
Why?
|
Drug Interactions | 16 | 2022 | 352 | 0.820 |
Why?
|
Forgiveness | 1 | 2021 | 2 | 0.820 |
Why?
|
Rectum | 3 | 2019 | 157 | 0.800 |
Why?
|
Acquired Immunodeficiency Syndrome | 3 | 2023 | 224 | 0.790 |
Why?
|
Ritonavir | 6 | 2012 | 70 | 0.780 |
Why?
|
Cross-Over Studies | 8 | 2023 | 456 | 0.780 |
Why?
|
Consumer Behavior | 1 | 2021 | 64 | 0.770 |
Why?
|
Hormones | 2 | 2022 | 135 | 0.750 |
Why?
|
Sustained Virologic Response | 2 | 2019 | 33 | 0.740 |
Why?
|
South Africa | 13 | 2023 | 163 | 0.740 |
Why?
|
Drug Administration Schedule | 12 | 2021 | 736 | 0.730 |
Why?
|
Pyridones | 6 | 2022 | 119 | 0.730 |
Why?
|
Biological Assay | 2 | 2018 | 122 | 0.680 |
Why?
|
Prenatal Exposure Delayed Effects | 2 | 2022 | 468 | 0.670 |
Why?
|
Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2018 | 2 | 0.670 |
Why?
|
Biomarkers, Pharmacological | 1 | 2018 | 26 | 0.660 |
Why?
|
Dextromethorphan | 1 | 2018 | 19 | 0.660 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2018 | 25 | 0.660 |
Why?
|
Kidney Function Tests | 3 | 2018 | 164 | 0.660 |
Why?
|
Pharmacogenomic Variants | 1 | 2018 | 35 | 0.650 |
Why?
|
Alcohol-Related Disorders | 2 | 2016 | 111 | 0.640 |
Why?
|
Solid Phase Extraction | 3 | 2014 | 19 | 0.630 |
Why?
|
Iohexol | 2 | 2015 | 21 | 0.630 |
Why?
|
Internet | 4 | 2017 | 633 | 0.620 |
Why?
|
Nucleosides | 4 | 2022 | 26 | 0.610 |
Why?
|
Training Support | 1 | 2017 | 24 | 0.610 |
Why?
|
Glomerular Filtration Rate | 5 | 2018 | 683 | 0.600 |
Why?
|
Reimbursement, Incentive | 1 | 2017 | 38 | 0.600 |
Why?
|
Diketopiperazines | 5 | 2022 | 8 | 0.590 |
Why?
|
Alanine | 6 | 2023 | 102 | 0.590 |
Why?
|
Indinavir | 4 | 2006 | 6 | 0.590 |
Why?
|
Deoxyguanine Nucleotides | 1 | 2016 | 8 | 0.580 |
Why?
|
Genitalia | 1 | 2016 | 27 | 0.580 |
Why?
|
Food Industry | 1 | 2016 | 14 | 0.570 |
Why?
|
Desiccation | 2 | 2014 | 17 | 0.570 |
Why?
|
Pierre Robin Syndrome | 1 | 2016 | 4 | 0.570 |
Why?
|
Harm Reduction | 1 | 2016 | 25 | 0.570 |
Why?
|
Diphosphates | 5 | 2021 | 16 | 0.560 |
Why?
|
Raltegravir Potassium | 2 | 2015 | 16 | 0.560 |
Why?
|
Sofosbuvir | 5 | 2022 | 52 | 0.560 |
Why?
|
Administration, Oral | 12 | 2021 | 756 | 0.550 |
Why?
|
Mandible | 1 | 2016 | 65 | 0.550 |
Why?
|
Erythrocytes | 6 | 2016 | 641 | 0.550 |
Why?
|
Craniofacial Abnormalities | 1 | 2016 | 58 | 0.540 |
Why?
|
Reproducibility of Results | 15 | 2023 | 2874 | 0.530 |
Why?
|
Drug Resistance, Viral | 5 | 2019 | 98 | 0.530 |
Why?
|
Genitalia, Female | 1 | 2015 | 40 | 0.520 |
Why?
|
Specimen Handling | 2 | 2014 | 165 | 0.520 |
Why?
|
Kenya | 7 | 2023 | 100 | 0.500 |
Why?
|
Bone Density | 5 | 2020 | 449 | 0.500 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2015 | 260 | 0.500 |
Why?
|
Cefoxitin | 1 | 2014 | 9 | 0.490 |
Why?
|
Contraceptive Devices, Female | 3 | 2019 | 9 | 0.490 |
Why?
|
Condoms | 4 | 2021 | 110 | 0.490 |
Why?
|
Lopinavir | 2 | 2013 | 29 | 0.470 |
Why?
|
Biomarkers | 8 | 2023 | 3588 | 0.460 |
Why?
|
Text Messaging | 5 | 2022 | 155 | 0.460 |
Why?
|
Viremia | 7 | 2023 | 132 | 0.460 |
Why?
|
Patient Compliance | 9 | 2017 | 537 | 0.460 |
Why?
|
Health Policy | 1 | 2016 | 333 | 0.460 |
Why?
|
Gastroesophageal Reflux | 1 | 2016 | 248 | 0.460 |
Why?
|
Half-Life | 7 | 2016 | 147 | 0.450 |
Why?
|
Immunologic Factors | 1 | 2015 | 225 | 0.440 |
Why?
|
HIV Seronegativity | 3 | 2010 | 24 | 0.430 |
Why?
|
Referral and Consultation | 2 | 2016 | 648 | 0.420 |
Why?
|
Aged | 21 | 2021 | 19657 | 0.420 |
Why?
|
Healthy Volunteers | 5 | 2019 | 201 | 0.420 |
Why?
|
Interrupted Time Series Analysis | 2 | 2022 | 45 | 0.410 |
Why?
|
Nontuberculous Mycobacteria | 1 | 2014 | 206 | 0.410 |
Why?
|
Sexual Partners | 4 | 2021 | 159 | 0.410 |
Why?
|
Unsafe Sex | 4 | 2021 | 57 | 0.400 |
Why?
|
Phosphates | 2 | 2015 | 167 | 0.400 |
Why?
|
Infant, Extremely Premature | 2 | 2023 | 58 | 0.400 |
Why?
|
Ribavirin | 4 | 2018 | 88 | 0.390 |
Why?
|
Lymphocyte Activation | 1 | 2015 | 1067 | 0.390 |
Why?
|
Self Report | 9 | 2023 | 699 | 0.390 |
Why?
|
Microsomes, Liver | 1 | 2010 | 59 | 0.390 |
Why?
|
Diabetic Nephropathies | 1 | 2014 | 289 | 0.380 |
Why?
|
Europe | 5 | 2020 | 356 | 0.380 |
Why?
|
HIV Integrase Inhibitors | 2 | 2021 | 60 | 0.380 |
Why?
|
Longitudinal Studies | 10 | 2023 | 2513 | 0.380 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 1 | 2010 | 4 | 0.380 |
Why?
|
Treatment Outcome | 16 | 2021 | 9342 | 0.380 |
Why?
|
Feeding Behavior | 1 | 2016 | 601 | 0.370 |
Why?
|
Inflammation | 3 | 2022 | 2566 | 0.370 |
Why?
|
Sex Factors | 9 | 2021 | 1781 | 0.370 |
Why?
|
Hepatitis C | 4 | 2022 | 217 | 0.360 |
Why?
|
Pregnancy | 11 | 2023 | 5690 | 0.360 |
Why?
|
Peritoneal Neoplasms | 1 | 2010 | 53 | 0.360 |
Why?
|
Drug Stability | 7 | 2014 | 153 | 0.360 |
Why?
|
Mobile Applications | 2 | 2022 | 147 | 0.360 |
Why?
|
Carcinoma, Small Cell | 1 | 2010 | 158 | 0.360 |
Why?
|
Macaca | 4 | 2023 | 54 | 0.360 |
Why?
|
Nucleotides | 3 | 2016 | 112 | 0.350 |
Why?
|
Hypothermia, Induced | 1 | 2010 | 68 | 0.350 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 2014 | 334 | 0.340 |
Why?
|
Central Nervous System Stimulants | 2 | 2022 | 142 | 0.340 |
Why?
|
Brazil | 7 | 2023 | 109 | 0.330 |
Why?
|
Airway Obstruction | 3 | 2016 | 168 | 0.330 |
Why?
|
Drug Therapy, Combination | 12 | 2019 | 965 | 0.320 |
Why?
|
Acrocephalosyndactylia | 3 | 2016 | 10 | 0.320 |
Why?
|
Child | 22 | 2022 | 19129 | 0.320 |
Why?
|
Metabolic Clearance Rate | 4 | 2018 | 113 | 0.310 |
Why?
|
Body Fluids | 5 | 2019 | 62 | 0.310 |
Why?
|
Drug Resistance, Multiple, Viral | 2 | 2017 | 11 | 0.310 |
Why?
|
Didanosine | 2 | 2006 | 13 | 0.300 |
Why?
|
Lung Diseases | 1 | 2014 | 718 | 0.300 |
Why?
|
Memory, Short-Term | 3 | 2015 | 233 | 0.300 |
Why?
|
Kidney Calculi | 1 | 2007 | 33 | 0.300 |
Why?
|
Gonadal Steroid Hormones | 1 | 2008 | 122 | 0.300 |
Why?
|
Sexual Behavior | 7 | 2022 | 437 | 0.290 |
Why?
|
Achievement | 3 | 2016 | 58 | 0.290 |
Why?
|
Placebos | 8 | 2020 | 202 | 0.290 |
Why?
|
Sarcoma | 2 | 2021 | 137 | 0.290 |
Why?
|
Piperazines | 2 | 2019 | 316 | 0.290 |
Why?
|
Coinfection | 3 | 2023 | 119 | 0.290 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2017 | 1945 | 0.290 |
Why?
|
Age Factors | 6 | 2021 | 2995 | 0.280 |
Why?
|
Pyrimidines | 2 | 2019 | 382 | 0.270 |
Why?
|
CD4 Lymphocyte Count | 5 | 2015 | 267 | 0.270 |
Why?
|
Anti-Bacterial Agents | 2 | 2021 | 1510 | 0.270 |
Why?
|
Sensitivity and Specificity | 9 | 2016 | 1795 | 0.270 |
Why?
|
Chromatography, High Pressure Liquid | 4 | 2015 | 490 | 0.270 |
Why?
|
HIV Reverse Transcriptase | 2 | 2012 | 27 | 0.270 |
Why?
|
Postpartum Period | 3 | 2023 | 271 | 0.270 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 3 | 2018 | 171 | 0.260 |
Why?
|
Infant, Newborn | 9 | 2023 | 5255 | 0.260 |
Why?
|
Fluorenes | 3 | 2020 | 37 | 0.260 |
Why?
|
Genotype | 7 | 2018 | 1882 | 0.260 |
Why?
|
Feasibility Studies | 8 | 2023 | 749 | 0.260 |
Why?
|
Post-Concussion Syndrome | 2 | 2019 | 137 | 0.250 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2012 | 2062 | 0.250 |
Why?
|
Polymorphism, Genetic | 4 | 2016 | 642 | 0.250 |
Why?
|
Hematocrit | 2 | 2016 | 91 | 0.250 |
Why?
|
Linear Models | 4 | 2016 | 827 | 0.250 |
Why?
|
Point-of-Care Systems | 2 | 2023 | 151 | 0.250 |
Why?
|
Benzimidazoles | 3 | 2020 | 140 | 0.240 |
Why?
|
Counseling | 3 | 2021 | 353 | 0.240 |
Why?
|
Gene Expression | 1 | 2009 | 1489 | 0.240 |
Why?
|
Hepatitis C, Chronic | 3 | 2019 | 151 | 0.240 |
Why?
|
Peru | 3 | 2021 | 59 | 0.240 |
Why?
|
Risk-Taking | 4 | 2019 | 319 | 0.240 |
Why?
|
Oxytocin | 1 | 2004 | 44 | 0.240 |
Why?
|
Area Under Curve | 6 | 2019 | 296 | 0.230 |
Why?
|
United States | 14 | 2021 | 12555 | 0.230 |
Why?
|
Child, Preschool | 13 | 2022 | 9491 | 0.230 |
Why?
|
Infant, Extremely Low Birth Weight | 1 | 2023 | 15 | 0.230 |
Why?
|
HIV Antibodies | 2 | 2021 | 50 | 0.220 |
Why?
|
Scotland | 1 | 2022 | 12 | 0.220 |
Why?
|
Telemedicine | 2 | 2022 | 664 | 0.220 |
Why?
|
Cross-Sectional Studies | 4 | 2021 | 4552 | 0.220 |
Why?
|
Patient Acceptance of Health Care | 2 | 2020 | 687 | 0.220 |
Why?
|
Peripartum Period | 1 | 2022 | 9 | 0.210 |
Why?
|
Case-Control Studies | 4 | 2021 | 3171 | 0.210 |
Why?
|
Calibration | 2 | 2013 | 135 | 0.210 |
Why?
|
Cohort Studies | 10 | 2023 | 5116 | 0.210 |
Why?
|
Commerce | 1 | 2022 | 56 | 0.210 |
Why?
|
United Kingdom | 2 | 2021 | 236 | 0.210 |
Why?
|
Sex Workers | 1 | 2021 | 5 | 0.210 |
Why?
|
Temperature | 2 | 2016 | 622 | 0.210 |
Why?
|
Cell Phone | 1 | 2022 | 81 | 0.210 |
Why?
|
Benchmarking | 2 | 2020 | 172 | 0.200 |
Why?
|
Sulfonamides | 3 | 2011 | 445 | 0.200 |
Why?
|
Magnetic Phenomena | 1 | 2021 | 10 | 0.200 |
Why?
|
Creatinine | 3 | 2018 | 491 | 0.200 |
Why?
|
Costs and Cost Analysis | 1 | 2022 | 202 | 0.200 |
Why?
|
Beer | 1 | 2021 | 6 | 0.200 |
Why?
|
Predictive Value of Tests | 4 | 2019 | 1868 | 0.200 |
Why?
|
Wine | 1 | 2021 | 8 | 0.200 |
Why?
|
Feedback, Psychological | 1 | 2021 | 20 | 0.200 |
Why?
|
Motivational Interviewing | 1 | 2022 | 84 | 0.200 |
Why?
|
Heterosexuality | 1 | 2021 | 30 | 0.200 |
Why?
|
New York City | 1 | 2021 | 75 | 0.200 |
Why?
|
Ethambutol | 1 | 2021 | 20 | 0.200 |
Why?
|
Plasma | 3 | 2015 | 224 | 0.200 |
Why?
|
RNA, Viral | 8 | 2023 | 572 | 0.200 |
Why?
|
Restaurants | 1 | 2021 | 17 | 0.200 |
Why?
|
Hepatitis B virus | 2 | 2023 | 25 | 0.200 |
Why?
|
Retrospective Studies | 8 | 2023 | 12978 | 0.200 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2015 | 3360 | 0.200 |
Why?
|
Infant | 7 | 2023 | 8293 | 0.200 |
Why?
|
Haplotypes | 3 | 2012 | 473 | 0.190 |
Why?
|
Meningitis, Cryptococcal | 1 | 2021 | 28 | 0.190 |
Why?
|
Cord Blood Stem Cell Transplantation | 1 | 2022 | 96 | 0.190 |
Why?
|
Latin America | 1 | 2021 | 74 | 0.190 |
Why?
|
Public Policy | 1 | 2021 | 62 | 0.190 |
Why?
|
Rifampin | 1 | 2021 | 69 | 0.190 |
Why?
|
Urocanic Acid | 1 | 2020 | 1 | 0.190 |
Why?
|
Semen | 1 | 2000 | 18 | 0.190 |
Why?
|
Cerebral Palsy | 1 | 2022 | 80 | 0.190 |
Why?
|
Communicable Disease Control | 1 | 2021 | 72 | 0.190 |
Why?
|
Azithromycin | 1 | 2021 | 81 | 0.190 |
Why?
|
Intimate Partner Violence | 1 | 2022 | 70 | 0.190 |
Why?
|
Cytokines | 2 | 2008 | 1900 | 0.190 |
Why?
|
Mycobacterium avium-intracellulare Infection | 1 | 2021 | 62 | 0.190 |
Why?
|
Australia | 6 | 2022 | 212 | 0.190 |
Why?
|
Vaginal Creams, Foams, and Jellies | 1 | 2020 | 6 | 0.190 |
Why?
|
Probenecid | 1 | 2019 | 9 | 0.180 |
Why?
|
Income | 1 | 2021 | 173 | 0.180 |
Why?
|
Family Characteristics | 1 | 2021 | 156 | 0.180 |
Why?
|
Time Factors | 5 | 2021 | 6412 | 0.180 |
Why?
|
Models, Biological | 2 | 2018 | 1715 | 0.180 |
Why?
|
Animals | 14 | 2023 | 33381 | 0.180 |
Why?
|
Drug Delivery Systems | 2 | 2023 | 306 | 0.180 |
Why?
|
Metronidazole | 1 | 2019 | 21 | 0.180 |
Why?
|
Monitoring, Ambulatory | 1 | 2020 | 84 | 0.180 |
Why?
|
Social Class | 1 | 2021 | 218 | 0.180 |
Why?
|
Drug Combinations | 1 | 2020 | 291 | 0.170 |
Why?
|
Drug Utilization | 2 | 2017 | 169 | 0.170 |
Why?
|
Bayes Theorem | 1 | 2021 | 344 | 0.170 |
Why?
|
Contrast Media | 2 | 2015 | 373 | 0.170 |
Why?
|
Antibodies, Neutralizing | 1 | 2021 | 228 | 0.170 |
Why?
|
Estradiol | 4 | 2023 | 476 | 0.170 |
Why?
|
Point-of-Care Testing | 1 | 2019 | 31 | 0.170 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 167 | 0.170 |
Why?
|
Stavudine | 1 | 2018 | 8 | 0.170 |
Why?
|
Infusions, Intravenous | 2 | 2014 | 380 | 0.170 |
Why?
|
Sexually Transmitted Diseases | 2 | 2018 | 155 | 0.170 |
Why?
|
Therapeutic Equivalency | 1 | 2018 | 18 | 0.170 |
Why?
|
Renal Insufficiency | 2 | 2018 | 150 | 0.170 |
Why?
|
Liquid Phase Microextraction | 1 | 2018 | 1 | 0.170 |
Why?
|
Vitrification | 1 | 2018 | 7 | 0.170 |
Why?
|
Cryoprotective Agents | 1 | 2018 | 12 | 0.170 |
Why?
|
Infusion Pumps, Implantable | 1 | 2018 | 20 | 0.170 |
Why?
|
Capsules | 1 | 2018 | 35 | 0.170 |
Why?
|
Blood Proteins | 1 | 2000 | 248 | 0.160 |
Why?
|
Fiber Optic Technology | 1 | 1998 | 19 | 0.160 |
Why?
|
Nanomedicine | 1 | 2018 | 28 | 0.160 |
Why?
|
Zimbabwe | 3 | 2023 | 39 | 0.160 |
Why?
|
Lab-On-A-Chip Devices | 1 | 2018 | 37 | 0.160 |
Why?
|
Sexually Transmitted Diseases, Viral | 1 | 2018 | 7 | 0.160 |
Why?
|
Antibodies, Monoclonal | 2 | 2023 | 1284 | 0.160 |
Why?
|
Pilot Projects | 5 | 2023 | 1419 | 0.160 |
Why?
|
Chemistry Techniques, Analytical | 1 | 2018 | 18 | 0.160 |
Why?
|
Mucus | 1 | 1998 | 54 | 0.160 |
Why?
|
Drug Compounding | 1 | 2018 | 90 | 0.160 |
Why?
|
Appendicitis | 1 | 2019 | 125 | 0.160 |
Why?
|
Impulsive Behavior | 1 | 2019 | 105 | 0.160 |
Why?
|
Intubation, Gastrointestinal | 1 | 1998 | 61 | 0.160 |
Why?
|
Carbamates | 2 | 2009 | 37 | 0.160 |
Why?
|
Mucous Membrane | 1 | 2018 | 113 | 0.160 |
Why?
|
Double-Blind Method | 5 | 2021 | 1687 | 0.160 |
Why?
|
Spine | 1 | 2019 | 144 | 0.150 |
Why?
|
Substrate Specificity | 1 | 2018 | 371 | 0.150 |
Why?
|
Radiosurgery | 1 | 2021 | 318 | 0.150 |
Why?
|
Schools | 3 | 2016 | 411 | 0.150 |
Why?
|
Cryopreservation | 1 | 2018 | 99 | 0.150 |
Why?
|
Microbial Sensitivity Tests | 2 | 2019 | 302 | 0.150 |
Why?
|
Follow-Up Studies | 8 | 2022 | 4596 | 0.150 |
Why?
|
Developmental Disabilities | 1 | 2020 | 247 | 0.150 |
Why?
|
Genes, MDR | 1 | 2017 | 2 | 0.150 |
Why?
|
Clinical Trials as Topic | 3 | 2016 | 969 | 0.150 |
Why?
|
Macaca mulatta | 3 | 2023 | 153 | 0.150 |
Why?
|
Anti-Infective Agents | 1 | 2020 | 227 | 0.150 |
Why?
|
Gels | 2 | 2015 | 72 | 0.150 |
Why?
|
Phosphorylation | 4 | 2015 | 1633 | 0.150 |
Why?
|
Seroconversion | 3 | 2022 | 48 | 0.150 |
Why?
|
Disease Models, Animal | 3 | 2016 | 3730 | 0.150 |
Why?
|
Bone Diseases | 1 | 2017 | 59 | 0.150 |
Why?
|
Absorptiometry, Photon | 4 | 2019 | 229 | 0.150 |
Why?
|
Quality Control | 2 | 2015 | 159 | 0.150 |
Why?
|
Inosine | 1 | 2016 | 12 | 0.150 |
Why?
|
Uganda | 3 | 2023 | 74 | 0.150 |
Why?
|
Direct-to-Consumer Advertising | 1 | 2016 | 4 | 0.150 |
Why?
|
Acute Disease | 1 | 2019 | 940 | 0.140 |
Why?
|
Enzymes | 1 | 2017 | 66 | 0.140 |
Why?
|
Aptitude Tests | 1 | 2016 | 3 | 0.140 |
Why?
|
Vitamin D Deficiency | 1 | 2018 | 162 | 0.140 |
Why?
|
Kidney | 4 | 2016 | 1353 | 0.140 |
Why?
|
Guanosine | 1 | 2016 | 39 | 0.140 |
Why?
|
Underage Drinking | 1 | 2016 | 17 | 0.140 |
Why?
|
Blastocystis Infections | 1 | 1996 | 1 | 0.140 |
Why?
|
Bronchoscopy | 1 | 1998 | 247 | 0.140 |
Why?
|
Directive Counseling | 1 | 2016 | 42 | 0.140 |
Why?
|
Anxiety | 1 | 2022 | 845 | 0.140 |
Why?
|
Reference Standards | 2 | 2020 | 176 | 0.140 |
Why?
|
Methanol | 1 | 2016 | 35 | 0.140 |
Why?
|
Intersectoral Collaboration | 1 | 2016 | 60 | 0.140 |
Why?
|
Spermatozoa | 1 | 2016 | 91 | 0.140 |
Why?
|
Bisexuality | 1 | 2016 | 16 | 0.140 |
Why?
|
Biological Transport | 1 | 2017 | 382 | 0.140 |
Why?
|
Purine-Nucleoside Phosphorylase | 2 | 2006 | 5 | 0.140 |
Why?
|
Mental Disorders | 2 | 2019 | 939 | 0.140 |
Why?
|
Bone and Bones | 1 | 2018 | 289 | 0.140 |
Why?
|
Alcoholic Intoxication | 1 | 2016 | 63 | 0.140 |
Why?
|
Antibiotic Prophylaxis | 1 | 2016 | 100 | 0.130 |
Why?
|
Mental Health Services | 1 | 2019 | 331 | 0.130 |
Why?
|
Solutions | 1 | 2016 | 156 | 0.130 |
Why?
|
Cyclohexanes | 1 | 2015 | 22 | 0.130 |
Why?
|
Cognition | 1 | 2022 | 1024 | 0.130 |
Why?
|
Saliva | 1 | 2016 | 188 | 0.130 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1996 | 113 | 0.130 |
Why?
|
Medication Reconciliation | 1 | 2015 | 25 | 0.130 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2023 | 984 | 0.130 |
Why?
|
Postoperative Period | 1 | 2016 | 309 | 0.130 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 191 | 0.130 |
Why?
|
Blood | 1 | 2015 | 100 | 0.130 |
Why?
|
Child Development | 2 | 2020 | 410 | 0.130 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2014 | 19 | 0.130 |
Why?
|
Health Care Costs | 1 | 2018 | 394 | 0.130 |
Why?
|
Adenosine | 1 | 2016 | 211 | 0.130 |
Why?
|
Brain Concussion | 2 | 2019 | 470 | 0.130 |
Why?
|
Intracellular Space | 1 | 2014 | 69 | 0.130 |
Why?
|
Injections, Intramuscular | 2 | 2021 | 116 | 0.130 |
Why?
|
Social Norms | 1 | 2014 | 23 | 0.120 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 98 | 0.120 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 628 | 0.120 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2018 | 296 | 0.120 |
Why?
|
Fetal Alcohol Spectrum Disorders | 1 | 2014 | 26 | 0.120 |
Why?
|
Down-Regulation | 1 | 2017 | 627 | 0.120 |
Why?
|
Single-Blind Method | 3 | 2019 | 269 | 0.120 |
Why?
|
Respiratory Tract Infections | 1 | 1998 | 331 | 0.120 |
Why?
|
Health Status Disparities | 1 | 2016 | 209 | 0.120 |
Why?
|
Triazoles | 1 | 2015 | 134 | 0.120 |
Why?
|
Community Health Services | 1 | 2016 | 212 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2021 | 1185 | 0.120 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 233 | 0.120 |
Why?
|
Risk Assessment | 3 | 2018 | 3057 | 0.120 |
Why?
|
Incidence | 5 | 2021 | 2424 | 0.120 |
Why?
|
Eating | 1 | 2016 | 369 | 0.120 |
Why?
|
Phenotype | 2 | 2019 | 3003 | 0.120 |
Why?
|
Glycerophospholipids | 2 | 2023 | 29 | 0.110 |
Why?
|
Multidrug Resistance-Associated Proteins | 3 | 2008 | 36 | 0.110 |
Why?
|
Spironolactone | 2 | 2023 | 34 | 0.110 |
Why?
|
T-Lymphocyte Subsets | 1 | 2015 | 396 | 0.110 |
Why?
|
Bone Neoplasms | 1 | 2015 | 199 | 0.110 |
Why?
|
Receptor, ErbB-2 | 1 | 2015 | 320 | 0.110 |
Why?
|
Water | 1 | 2016 | 425 | 0.110 |
Why?
|
Sleep Deprivation | 1 | 2015 | 164 | 0.110 |
Why?
|
Administration, Topical | 2 | 2015 | 141 | 0.110 |
Why?
|
Premature Birth | 1 | 2016 | 284 | 0.110 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 942 | 0.110 |
Why?
|
Victoria | 2 | 2023 | 13 | 0.110 |
Why?
|
Uropathogenic Escherichia coli | 1 | 2011 | 2 | 0.110 |
Why?
|
Computer Simulation | 1 | 2016 | 922 | 0.110 |
Why?
|
Aged, 80 and over | 3 | 2018 | 6561 | 0.100 |
Why?
|
Pravastatin | 1 | 2011 | 29 | 0.100 |
Why?
|
Organic Anion Transporters | 1 | 2011 | 19 | 0.100 |
Why?
|
Prevalence | 4 | 2021 | 2326 | 0.100 |
Why?
|
Decision Making | 1 | 2019 | 809 | 0.100 |
Why?
|
Cystitis | 1 | 2011 | 21 | 0.100 |
Why?
|
Proline | 1 | 2012 | 71 | 0.100 |
Why?
|
Cystic Fibrosis | 1 | 2021 | 964 | 0.100 |
Why?
|
Testosterone | 2 | 2022 | 351 | 0.100 |
Why?
|
Anion Exchange Resins | 1 | 2011 | 7 | 0.100 |
Why?
|
Fibrosis | 1 | 2014 | 483 | 0.100 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2011 | 48 | 0.100 |
Why?
|
Students | 1 | 2016 | 509 | 0.100 |
Why?
|
Sarcoma, Ewing | 2 | 2015 | 65 | 0.100 |
Why?
|
Metabolic Detoxication, Phase I | 1 | 2010 | 4 | 0.100 |
Why?
|
Food-Drug Interactions | 1 | 2010 | 6 | 0.100 |
Why?
|
Escherichia coli Infections | 1 | 2011 | 105 | 0.100 |
Why?
|
T-Lymphocytes | 2 | 2018 | 1774 | 0.100 |
Why?
|
Guidelines as Topic | 1 | 2013 | 262 | 0.100 |
Why?
|
Immunotherapy | 1 | 2015 | 493 | 0.100 |
Why?
|
Antacids | 1 | 2010 | 15 | 0.100 |
Why?
|
Pyrrolidinones | 1 | 2010 | 25 | 0.100 |
Why?
|
Emergency Service, Hospital | 3 | 2019 | 1864 | 0.100 |
Why?
|
Multivariate Analysis | 2 | 2016 | 1474 | 0.100 |
Why?
|
Smoking | 1 | 2018 | 1487 | 0.100 |
Why?
|
Epithelial Cells | 1 | 2016 | 963 | 0.090 |
Why?
|
Infusions, Parenteral | 1 | 2010 | 37 | 0.090 |
Why?
|
Virulence Factors | 1 | 2011 | 140 | 0.090 |
Why?
|
Memory Disorders | 1 | 2011 | 168 | 0.090 |
Why?
|
Substance-Related Disorders | 1 | 2018 | 971 | 0.090 |
Why?
|
Bluetongue | 1 | 2009 | 4 | 0.090 |
Why?
|
Escherichia coli Proteins | 1 | 2011 | 170 | 0.090 |
Why?
|
Administration, Intravaginal | 2 | 2020 | 21 | 0.090 |
Why?
|
Cattle Diseases | 1 | 2009 | 15 | 0.090 |
Why?
|
Twist-Related Protein 1 | 1 | 2009 | 10 | 0.090 |
Why?
|
Tablets | 2 | 2022 | 35 | 0.090 |
Why?
|
Combined Modality Therapy | 2 | 2010 | 1166 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 842 | 0.090 |
Why?
|
Molecular Structure | 1 | 2010 | 459 | 0.090 |
Why?
|
Sleep | 1 | 2015 | 660 | 0.090 |
Why?
|
Cost-Benefit Analysis | 1 | 2012 | 554 | 0.090 |
Why?
|
Vagina | 2 | 2022 | 148 | 0.080 |
Why?
|
Immunity, Cellular | 1 | 2010 | 270 | 0.080 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2008 | 21 | 0.080 |
Why?
|
Los Angeles | 2 | 2019 | 60 | 0.080 |
Why?
|
Colorado | 1 | 2018 | 4196 | 0.080 |
Why?
|
Tracheal Diseases | 1 | 2008 | 16 | 0.080 |
Why?
|
DNA Primers | 2 | 2006 | 533 | 0.080 |
Why?
|
Research Design | 1 | 2014 | 969 | 0.080 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2009 | 156 | 0.080 |
Why?
|
Gadolinium DTPA | 1 | 2008 | 54 | 0.080 |
Why?
|
Demography | 2 | 2022 | 274 | 0.080 |
Why?
|
Electronic Health Records | 1 | 2015 | 829 | 0.080 |
Why?
|
Oxidation-Reduction | 1 | 2010 | 940 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 387 | 0.080 |
Why?
|
DNA | 1 | 2014 | 1388 | 0.080 |
Why?
|
Recombinant Proteins | 1 | 2010 | 1308 | 0.080 |
Why?
|
Receptors, Pheromone | 1 | 2006 | 2 | 0.070 |
Why?
|
Kinetics | 1 | 2010 | 1624 | 0.070 |
Why?
|
Animal Communication | 1 | 2006 | 16 | 0.070 |
Why?
|
Pyrimidinones | 1 | 2007 | 86 | 0.070 |
Why?
|
Wounds and Injuries | 1 | 2014 | 772 | 0.070 |
Why?
|
Liver | 2 | 2013 | 1816 | 0.070 |
Why?
|
Survival Analysis | 1 | 2010 | 1267 | 0.070 |
Why?
|
Adipocytes | 1 | 2008 | 199 | 0.070 |
Why?
|
Abnormalities, Multiple | 1 | 2008 | 181 | 0.070 |
Why?
|
Moths | 1 | 2006 | 36 | 0.070 |
Why?
|
Sequence Analysis, DNA | 1 | 2009 | 755 | 0.070 |
Why?
|
Neoplasm Staging | 1 | 2010 | 1223 | 0.070 |
Why?
|
Esomeprazole | 1 | 2006 | 6 | 0.070 |
Why?
|
Anti-Ulcer Agents | 1 | 2006 | 16 | 0.070 |
Why?
|
Ribosomal Proteins | 1 | 2006 | 68 | 0.070 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 245 | 0.070 |
Why?
|
Pharmacology, Clinical | 1 | 2006 | 8 | 0.070 |
Why?
|
Olfactory Receptor Neurons | 1 | 2006 | 67 | 0.070 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2006 | 111 | 0.070 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 1125 | 0.070 |
Why?
|
Base Sequence | 2 | 2006 | 2159 | 0.070 |
Why?
|
Education | 1 | 2006 | 105 | 0.070 |
Why?
|
Medical History Taking | 2 | 2016 | 120 | 0.070 |
Why?
|
Psychotherapy, Brief | 1 | 2005 | 32 | 0.070 |
Why?
|
Proton Pump Inhibitors | 1 | 2006 | 98 | 0.060 |
Why?
|
Lymphocytes | 1 | 2007 | 347 | 0.060 |
Why?
|
Blood Glucose | 1 | 2014 | 1939 | 0.060 |
Why?
|
Lymphopenia | 1 | 2004 | 48 | 0.060 |
Why?
|
World Health Organization | 1 | 2005 | 107 | 0.060 |
Why?
|
Nuclear Proteins | 1 | 2009 | 597 | 0.060 |
Why?
|
Socioeconomic Factors | 2 | 2019 | 1129 | 0.060 |
Why?
|
Surveys and Questionnaires | 3 | 2021 | 4708 | 0.060 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 2871 | 0.060 |
Why?
|
International Cooperation | 1 | 2005 | 177 | 0.060 |
Why?
|
Mitochondrial Proteins | 1 | 2006 | 226 | 0.060 |
Why?
|
Deoxyadenosines | 1 | 2023 | 6 | 0.060 |
Why?
|
Proviruses | 1 | 2023 | 9 | 0.060 |
Why?
|
Community Mental Health Services | 1 | 2004 | 83 | 0.060 |
Why?
|
Canrenone | 1 | 2023 | 1 | 0.060 |
Why?
|
Logistic Models | 2 | 2019 | 1901 | 0.060 |
Why?
|
Immunoassay | 1 | 2003 | 101 | 0.060 |
Why?
|
Treatment Failure | 2 | 2020 | 341 | 0.060 |
Why?
|
Polymerase Chain Reaction | 1 | 2006 | 1012 | 0.060 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2006 | 348 | 0.060 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 78 | 0.060 |
Why?
|
Recovery of Function | 1 | 2007 | 604 | 0.060 |
Why?
|
Gestational Age | 2 | 2016 | 765 | 0.050 |
Why?
|
Rilpivirine | 1 | 2022 | 3 | 0.050 |
Why?
|
Telephone | 1 | 2023 | 152 | 0.050 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 2022 | 52 | 0.050 |
Why?
|
Body Weight | 2 | 2018 | 934 | 0.050 |
Why?
|
Blood Cells | 1 | 2022 | 39 | 0.050 |
Why?
|
Trust | 1 | 2023 | 113 | 0.050 |
Why?
|
Benin | 1 | 2021 | 5 | 0.050 |
Why?
|
Africa South of the Sahara | 1 | 2021 | 37 | 0.050 |
Why?
|
Safe Sex | 1 | 2021 | 18 | 0.050 |
Why?
|
Sex Work | 1 | 2021 | 17 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2018 | 1244 | 0.050 |
Why?
|
Feces | 2 | 2011 | 396 | 0.050 |
Why?
|
Intention to Treat Analysis | 1 | 2021 | 70 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2015 | 3174 | 0.050 |
Why?
|
Switzerland | 1 | 2021 | 27 | 0.050 |
Why?
|
Mutation | 3 | 2017 | 3457 | 0.050 |
Why?
|
Antibiotics, Antitubercular | 1 | 2021 | 35 | 0.050 |
Why?
|
Netherlands | 1 | 2021 | 62 | 0.050 |
Why?
|
Re-Irradiation | 1 | 2021 | 8 | 0.050 |
Why?
|
Immunotoxins | 2 | 1991 | 35 | 0.050 |
Why?
|
Risk | 2 | 2021 | 853 | 0.050 |
Why?
|
Neoplasms | 2 | 2014 | 2179 | 0.050 |
Why?
|
Colombia | 1 | 2021 | 43 | 0.050 |
Why?
|
Crisis Intervention | 1 | 2021 | 25 | 0.050 |
Why?
|
Siblings | 1 | 2022 | 235 | 0.050 |
Why?
|
Feedback | 1 | 2021 | 153 | 0.050 |
Why?
|
Drug Resistance | 1 | 2021 | 167 | 0.050 |
Why?
|
Delayed-Action Preparations | 1 | 2021 | 161 | 0.050 |
Why?
|
Glucuronides | 1 | 2000 | 13 | 0.050 |
Why?
|
Cephalometry | 1 | 2020 | 28 | 0.050 |
Why?
|
Mexico | 1 | 2021 | 165 | 0.050 |
Why?
|
Sperm Motility | 1 | 2020 | 28 | 0.050 |
Why?
|
Pregnancy Outcome | 1 | 2023 | 349 | 0.050 |
Why?
|
Mycobacterium avium Complex | 1 | 2021 | 93 | 0.050 |
Why?
|
Hepacivirus | 1 | 2022 | 230 | 0.050 |
Why?
|
Fetal Blood | 1 | 2022 | 272 | 0.050 |
Why?
|
Soft Tissue Neoplasms | 1 | 2021 | 93 | 0.050 |
Why?
|
Proof of Concept Study | 1 | 2020 | 46 | 0.050 |
Why?
|
Regression Analysis | 2 | 2019 | 983 | 0.050 |
Why?
|
Protease Inhibitors | 1 | 2020 | 102 | 0.050 |
Why?
|
Bacteroides fragilis | 1 | 2019 | 11 | 0.050 |
Why?
|
Acyclovir | 1 | 2000 | 105 | 0.050 |
Why?
|
Lipodystrophy | 1 | 1999 | 18 | 0.050 |
Why?
|
Radiation Injuries | 1 | 2021 | 131 | 0.040 |
Why?
|
Antitubercular Agents | 1 | 2021 | 163 | 0.040 |
Why?
|
Herpes Simplex | 1 | 2000 | 90 | 0.040 |
Why?
|
North America | 1 | 2020 | 266 | 0.040 |
Why?
|
Hip | 1 | 2019 | 46 | 0.040 |
Why?
|
Monte Carlo Method | 1 | 2019 | 146 | 0.040 |
Why?
|
Lymphoid Tissue | 1 | 2019 | 65 | 0.040 |
Why?
|
Intestine, Large | 1 | 2018 | 15 | 0.040 |
Why?
|
Health Promotion | 1 | 2005 | 691 | 0.040 |
Why?
|
Spain | 1 | 2018 | 34 | 0.040 |
Why?
|
Public Health Surveillance | 1 | 2018 | 58 | 0.040 |
Why?
|
Uridine Monophosphate | 1 | 2018 | 15 | 0.040 |
Why?
|
Oils | 1 | 2018 | 19 | 0.040 |
Why?
|
Dimethyl Sulfoxide | 1 | 2018 | 45 | 0.040 |
Why?
|
Safety | 1 | 2020 | 304 | 0.040 |
Why?
|
Cervix Uteri | 1 | 2018 | 48 | 0.040 |
Why?
|
Administration, Cutaneous | 1 | 2018 | 119 | 0.040 |
Why?
|
Organic Anion Transport Protein 1 | 2 | 2008 | 6 | 0.040 |
Why?
|
Furans | 2 | 2009 | 23 | 0.040 |
Why?
|
Lymphogranuloma Venereum | 1 | 2017 | 2 | 0.040 |
Why?
|
Solvents | 1 | 2018 | 118 | 0.040 |
Why?
|
Urinalysis | 1 | 2018 | 68 | 0.040 |
Why?
|
Thailand | 1 | 2017 | 10 | 0.040 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 178 | 0.040 |
Why?
|
Rats, Sprague-Dawley | 1 | 2023 | 2478 | 0.040 |
Why?
|
Interviews as Topic | 1 | 2020 | 599 | 0.040 |
Why?
|
Breast Neoplasms | 1 | 2009 | 1965 | 0.040 |
Why?
|
California | 1 | 2018 | 382 | 0.040 |
Why?
|
Nanotechnology | 1 | 2018 | 120 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2021 | 527 | 0.040 |
Why?
|
Membrane Transport Proteins | 2 | 2008 | 136 | 0.040 |
Why?
|
Cities | 1 | 2017 | 96 | 0.040 |
Why?
|
Equipment Design | 1 | 2018 | 519 | 0.040 |
Why?
|
Defective Viruses | 1 | 2016 | 4 | 0.040 |
Why?
|
Quality of Life | 2 | 2023 | 2366 | 0.040 |
Why?
|
Hepatitis B, Chronic | 1 | 2016 | 18 | 0.030 |
Why?
|
Parathyroid Hormone | 1 | 2016 | 99 | 0.030 |
Why?
|
District of Columbia | 1 | 2016 | 27 | 0.030 |
Why?
|
Binge Drinking | 1 | 2016 | 35 | 0.030 |
Why?
|
San Francisco | 1 | 2016 | 57 | 0.030 |
Why?
|
Florida | 1 | 2016 | 73 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2017 | 136 | 0.030 |
Why?
|
Hepatitis B | 1 | 2016 | 52 | 0.030 |
Why?
|
Syphilis | 1 | 2016 | 26 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2003 | 2674 | 0.030 |
Why?
|
Neuroectodermal Tumors | 1 | 2015 | 1 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 900 | 0.030 |
Why?
|
Reproductive Health | 1 | 2016 | 68 | 0.030 |
Why?
|
Vitamin D | 1 | 2018 | 354 | 0.030 |
Why?
|
Plant Preparations | 1 | 2015 | 23 | 0.030 |
Why?
|
Observer Variation | 1 | 2016 | 309 | 0.030 |
Why?
|
Chlamydia Infections | 1 | 2016 | 65 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2018 | 477 | 0.030 |
Why?
|
Gross Domestic Product | 1 | 2014 | 1 | 0.030 |
Why?
|
Qualitative Research | 1 | 2020 | 953 | 0.030 |
Why?
|
Gonorrhea | 1 | 2016 | 54 | 0.030 |
Why?
|
Population | 1 | 2015 | 30 | 0.030 |
Why?
|
Filtration | 1 | 2015 | 64 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2016 | 238 | 0.030 |
Why?
|
Nonlinear Dynamics | 1 | 2015 | 89 | 0.030 |
Why?
|
Protein Binding | 1 | 2000 | 1975 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2015 | 185 | 0.030 |
Why?
|
Africa | 1 | 2015 | 100 | 0.030 |
Why?
|
Accidents, Traffic | 1 | 2016 | 178 | 0.030 |
Why?
|
Comorbidity | 1 | 2019 | 1527 | 0.030 |
Why?
|
Diphtheria Toxin | 2 | 1991 | 63 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2015 | 107 | 0.030 |
Why?
|
Lipids | 1 | 2018 | 607 | 0.030 |
Why?
|
Hepatocytes | 1 | 2015 | 205 | 0.030 |
Why?
|
Nonprescription Drugs | 1 | 2015 | 67 | 0.030 |
Why?
|
Rats | 1 | 2023 | 5392 | 0.030 |
Why?
|
Osteosarcoma | 1 | 2015 | 71 | 0.030 |
Why?
|
Cytoplasm | 1 | 2015 | 269 | 0.030 |
Why?
|
Forecasting | 1 | 2016 | 353 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2014 | 73 | 0.030 |
Why?
|
Educational Status | 1 | 2016 | 437 | 0.030 |
Why?
|
Albuminuria | 1 | 2015 | 195 | 0.030 |
Why?
|
Mental Health | 1 | 2019 | 568 | 0.030 |
Why?
|
ROC Curve | 1 | 2015 | 473 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2019 | 531 | 0.030 |
Why?
|
DNA, Viral | 1 | 2016 | 356 | 0.030 |
Why?
|
Mitochondria | 1 | 1999 | 786 | 0.030 |
Why?
|
Vitamins | 1 | 2015 | 158 | 0.030 |
Why?
|
Interleukin-2 | 2 | 1991 | 416 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 298 | 0.030 |
Why?
|
Prescription Drugs | 1 | 2015 | 113 | 0.030 |
Why?
|
Adiposity | 1 | 2018 | 516 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2019 | 781 | 0.030 |
Why?
|
Depression | 1 | 2021 | 1132 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 544 | 0.030 |
Why?
|
General Practice | 1 | 2013 | 26 | 0.030 |
Why?
|
Monocytes | 1 | 2015 | 513 | 0.030 |
Why?
|
Sample Size | 1 | 2013 | 133 | 0.030 |
Why?
|
Reimbursement Mechanisms | 1 | 2013 | 79 | 0.030 |
Why?
|
New South Wales | 1 | 2011 | 10 | 0.030 |
Why?
|
Recurrence | 1 | 2015 | 975 | 0.030 |
Why?
|
Inservice Training | 1 | 2013 | 106 | 0.030 |
Why?
|
Global Health | 1 | 2014 | 310 | 0.030 |
Why?
|
Darunavir | 1 | 2011 | 17 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 2 | 1991 | 653 | 0.030 |
Why?
|
Urine | 1 | 2011 | 59 | 0.030 |
Why?
|
Proteins | 1 | 2018 | 938 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2013 | 230 | 0.030 |
Why?
|
Physician Assistants | 1 | 2013 | 68 | 0.030 |
Why?
|
Ambulatory Care | 1 | 2015 | 482 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 481 | 0.020 |
Why?
|
Nurse Practitioners | 1 | 2013 | 107 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2015 | 467 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2015 | 632 | 0.020 |
Why?
|
Models, Statistical | 1 | 2015 | 636 | 0.020 |
Why?
|
Candida | 1 | 2010 | 35 | 0.020 |
Why?
|
Transsexualism | 1 | 2010 | 17 | 0.020 |
Why?
|
Public Health | 1 | 2015 | 450 | 0.020 |
Why?
|
Computer-Assisted Instruction | 1 | 2011 | 66 | 0.020 |
Why?
|
Risk Factors | 2 | 2019 | 9000 | 0.020 |
Why?
|
Body Mass Index | 1 | 2018 | 2092 | 0.020 |
Why?
|
Nausea | 1 | 2010 | 107 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 539 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2015 | 671 | 0.020 |
Why?
|
Cholesterol | 1 | 2011 | 373 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2009 | 68 | 0.020 |
Why?
|
Triglycerides | 1 | 2011 | 519 | 0.020 |
Why?
|
Athletic Injuries | 1 | 2016 | 495 | 0.020 |
Why?
|
Prodrugs | 1 | 2009 | 44 | 0.020 |
Why?
|
Motivation | 1 | 2013 | 506 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2009 | 381 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2021 | 2220 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 681 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 1440 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2008 | 287 | 0.020 |
Why?
|
Point Mutation | 1 | 2008 | 228 | 0.020 |
Why?
|
Serum | 1 | 2007 | 63 | 0.020 |
Why?
|
Fatty Alcohols | 1 | 2006 | 5 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2010 | 736 | 0.020 |
Why?
|
Platelet Count | 1 | 2007 | 83 | 0.020 |
Why?
|
Electric Conductivity | 1 | 2006 | 91 | 0.020 |
Why?
|
Pheromones | 1 | 2006 | 29 | 0.020 |
Why?
|
Cattle | 1 | 2009 | 978 | 0.020 |
Why?
|
Parents | 1 | 2015 | 1212 | 0.020 |
Why?
|
Software | 1 | 2011 | 613 | 0.020 |
Why?
|
Gene Frequency | 1 | 2008 | 513 | 0.020 |
Why?
|
Quebec | 1 | 2006 | 5 | 0.020 |
Why?
|
Ion Exchange | 1 | 2006 | 1 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2007 | 305 | 0.020 |
Why?
|
Chemical Fractionation | 1 | 2006 | 29 | 0.020 |
Why?
|
Species Specificity | 1 | 2006 | 565 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 2436 | 0.020 |
Why?
|
Algorithms | 2 | 2004 | 1541 | 0.020 |
Why?
|
Internationality | 1 | 2006 | 152 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2007 | 649 | 0.020 |
Why?
|
Action Potentials | 1 | 2006 | 420 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 827 | 0.010 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 239 | 0.010 |
Why?
|
Alleles | 1 | 2006 | 832 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2010 | 2275 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2010 | 4077 | 0.010 |
Why?
|
Survival Rate | 1 | 2007 | 1720 | 0.010 |
Why?
|
Shiga Toxins | 2 | 1991 | 3 | 0.010 |
Why?
|
Apoptosis | 1 | 2010 | 2484 | 0.010 |
Why?
|
Bacterial Toxins | 2 | 1991 | 106 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2009 | 2275 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 2000 | 200 | 0.010 |
Why?
|
Protein Engineering | 1 | 1990 | 107 | 0.010 |
Why?
|